Oculis宣布第一名患者在Licaminlimab治疗干眼病的PREDICT-1注册试验中随机分配

2026-06-09 16:16

PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DED
This FDA-aligned trial targets the specific TNFR1 genotype to maximize treatment effects, with ~70% of clinical sites already activated and patients in the run-in phase
With only 13% of DED patients experiencing sustained relief, Licaminlimab has the potential to offer a targeted precision solution for a highly unsatisfied market